FDA warned NeilMed Pharmaceuticals that its OTC drug manufacturing had current good manufacturing practice violations, including missing glycerin identity testing and dirty equipment.
What happened
FDA inspected NeilMed's drug manufacturing facility at 601 Aviation Boulevard, Santa Rosa, California, from November 28 to December 2, 2022. The agency found that the firm did not perform required identity testing on incoming components such as glycerin to detect diethylene glycol or ethylene glycol, relied on supplier certificates and an unqualified supplier, and had visible residues on product-contact surfaces of non-dedicated mixing tanks labeled cleaned, with missing cleaning logs. FDA also found multiple objectionable microbial contamination findings and inadequate investigations of out-of-specification bioburden results.
What FDA found
The firm did not perform at least one identity test for each incoming component, including glycerin, and did not validate the reliability of supplier test analyses.
21 CFR 211.84(d)(1) and 211.84(d)(2)The firm released one lot of glycerin from an unqualified supplier to make Clear Canal batches and relied on the manufacturer's certificate of analysis.
21 CFR 211.84(d)(1) and 211.84(d)(2)The firm failed to adequately clean and maintain equipment; investigators saw unidentified visible residues on direct product-contact surfaces in non-dedicated mixing tanks labeled cleaned, and cleaning and usage logs were missing.
21 CFR 211.67(a)The firm's investigation of out-of-specification bioburden results for Burkholderia cepacia complex, yeast, and mold did not cover all potentially affected drug product batches and did not prevent recurrence.
Because the firm's methods, facilities, or controls for manufacturing did not conform to current good manufacturing practice (CGMP), its drug products are adulterated, meaning they are legally considered unsafe or not meeting requirements.
FD&C Act section 501(a)(2)(B), 21 U.S.C. 351(a)(2)(B)
What FDA wants
FDA tells NeilMed to correct the violations promptly and respond in writing within 15 working days, including a comprehensive material-system review, DEG/EG testing of retain samples within 30 days, a risk assessment for products within expiry, and cleaning and CAPA assessments. FDA also strongly recommends engaging a qualified CGMP consultant.
Who should pay attention
- brands that buy OTC drug products from NeilMed
- drugmakers using glycerin or propylene glycol in oral or nasal products
- quality teams responsible for supplier qualification, incoming testing, and cleaning validation
This is a summary. Read the original letter on fda.gov.